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Abstract Amyotrophic lateral sclerosis (ALS) is a rare
neurodegenerative disease that affects upper and lower
motor neurons in the brain and spinal cord, with
progressive weakness and atrophy of most muscles in
the body and is almost always fatal within 3–5 years. A
small proportion of cases are familial, and remarkable
achievements have been made during the last years in
understanding the genetics of the disease. In spite of this,
the basic pathogenic mechanisms underlying the sporadic
disease are still poorly understood. There is urgent need
for better understanding of the pathogenic processes in
order to be able to develop effective treatments. The
present review will focus on recent knowledge gained in
diagnosis, genetics, pathogenesis and therapies in ALS.
Future development of diagnostic technologies integrat-
ing genetic, environmental and individual information
will enable us to predict a population at risk for ALS.
New treatments actually in development will help
improve the medical management of ALS patients,
taking into consideration individual traits, as genetic
background, and pave a way for a more effective
personalized diagnostic and treatment approach.
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Background
Amyotrophic Lateral Sclerosis (ALS), also known as Lou
Gehrig’s disease or Maladie de Charcot, is a progressive,
fatal neurodegenerative disease, which causes premature
selective death of motor neurons in the primary motor
cortex, corticospinal tracts, brainstem and spinal cord. It
affects lower motor neurons (LMN) that reside in the
anterior horns of the spinal cord and in the brain stem;
corticospinal upper motor neurons (UMN) that reside in the
precentral gyrus of the brain cortex; and, frequently,
prefrontal motor neurons that are involved in planning or
orchestrating the work of both UMN and LMN [1]. It
progresses rapidly to cause denervation and ultimately
weakness of most muscles of the body. The disease is
almost always fatal and results in death due to paralysis of
the respiratory muscles within 3–5 years of onset [2].
Epidemiology
The incidence of ALS is around 1.8–2.5 per 100,000/year
and is evenly distributed across Europe and North America
[3]. An unusually high incidence was reported around the
Pacific ring, on Guam [4], and the Kii peninsula in Japan
[5]. Men are slightly more affected than women, with a
male: female ratio about 1.5:1, although more recent data
suggest that this ratio is smaller, approaching one [6, 7].
The age of onset of sporadic ALS is very variable, from the
third to the ninth decade, with a mean of 63 years [8].
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Clinical features
The clinical features of ALS are a direct consequence of the
progressive loss of upper and lower motor neurons, with
secondary denervation and subsequent reinnervation of
muscles. As long as reinnervation can compensate for
denervation, clinical weakness may not be detectable. How-
ever, as the motor units grow larger and their number begins to
decrease, the earliest consequence is that affected muscles may
fatigue faster than muscles with normal motor units; conse-
quently, one of the first symptoms of ALS may be increased
fatigue. As the number of motor units innervating a muscle
decreases further, reinnervation is no longer able to compensate
for denervation, permanent weakness develops and progresses
and the affected muscles gradually undergo atrophy.
The parts of the body affected by early symptoms in
ALS depend on which motor neurons are damaged first. In
about 75% of patients the disease starts with weakness of
lower or upper limb muscles, and patients experience
tripping or stumbling, difficulty with tasks such as
buttoning a shirt or writing. Affected muscles may develop
twitching, cramping, or stiffness (limb form). In the other
25% of cases the site of onset is the motor nuclei in the
brainstem and/or their coticobulbar neurons. These patients
experience first slurred and nasal speech, followed by
difficulty speaking clearly, difficulty swallowing and loss of
tongue mobility (bulbar form).
Regardless of the region of the body first affected,
muscle weakness and atrophy spread to other regions of the
body as the disease progresses. Patients experience increasing
difficulty moving, swallowing (dysphagia), and speaking or
forming words (dysarthria). The ineffective swallowing of
saliva leads to excessive drooling (sialorrhea). Weakness of
breathing muscles leads to respiratory insufficiency.
At neurological examination, a combination of UMN and
LMN signs can be found: symptoms of UMN involvement
include increased muscle tone (spasticity), exaggerated
reflexes (hyperreflexia), pathological pyramidal signs such
as extensor plantar responses, loss of dexterity in the presence
of normal strength. Symptoms of LMN degeneration include
muscle atrophy (Fig. 1) and twitching (fasciculations),
diminished to absent tendon reflexes. Fasciculations are not
specific for ALS, but can be found in other peripheral
nervous system diseases and also at times in healthy
individuals, although a finding of large and fast-firing
fasciculations at many sites is very indicative for the disease.
Around 15–45% of patients experience uncontrollable
emotional symptoms, as inappropriate laughter, crying or
smiling, a feature that is associated with speech and swallow-
ing disturbances in the complex of pseudobulbar syndrome,
characteristic of bilateral corticobulbar tracts involvement.
Although the sequence of emerging symptoms and the
rate of disease progression are variable, most patients will
develop with time major disability in all motor tasks, will
not be able to stand or walk, or use their hands and arms.
Difficulty swallowing and chewing impair the patient’s
ability to eat and increase the risk of choking and
pulmonary infections. Loss of weight is a consequence of
impaired nutrition and muscle wasting. Because the disease
usually does not affect cognitive abilities, patients are aware
of their progressive loss of function and may become
anxious and depressed. On the other hand, the preserved
cognition enables patients to take decisions, including those
related to their own end-of-life, by themselves, even after
they reach a totally immobile state (locked-in).
Up to 50% of patients experience mild difficulties with
word generation, attention, or decision making. 5–10%
develop overt frontotemporal dementia, characterized by
personality changes and impairment of executive functions
and language; this is more common among those with a
family history of dementia [9].
As the diaphragm and intercostal muscles weaken,
forced vital capacity and inspiratory pressure diminish.
Most patients with ALS die of respiratory failure or
pneumonia [10]. Death usually occurs within two to five
years of diagnosis (median 27 months). Less than 5% of
patients survive more than 10 years. 6% have an arrested
form of disease. In general, survival is better for younger
patients and those with limb onset [11].
Interestingly, there are few motor functions that are
usually not affected in ALS: control of eye muscles is the
most preserved function, although some patients with an
extremely long duration of disease (more than 20 years)
may lose eye control too. Bladder and bowel control are
usually preserved as well, although as a result of immobility
and diet changes, intestinal problems such as constipation can
require intensive management.
Diagnosis
Diagnostic criteria for ALS were developed by expert
consensus (El Escorial criteria, [12]). By El Escorial criteria
Fig. 1 Atrophy of thenar eminence and weakness of finger extensors,
more prominent on the right, in a 70-years-old woman with symptoms
of ALS for 6 months
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the diagnosis of ALS requires all of the following: evidence
of UMN degeneration by clinical examination, evidence of
LMN degeneration by clinical, electrophysiological or
neuropathological examination, evidence of progressive
spread of symptoms or signs within a region or to other
regions, in the absence of electrophysiological, neuroimag-
ing and pathological evidence of other disease processes that
might explain the clinical picture.
The El Escorial criteria define categories of clinical
diagnostic certainty. For this purpose four body regions
were defined: bulbar, including tongue and neck muscles,
cervical, thoracic and lumbar. The diagnosis of ALS should
be regarded as definite when UMN and LMN signs are
found in three body regions. Probable ALS is defined as
either UMN and LMN signs in two regions with at least
some UMN signs rostral to LMN signs, or UMN signs in
one or more regions and LMN signs by electromyography
(EMG) in at least two regions. Possible ALS is the least
certain degree and is defined as UMN and LMN signs in a
single body region, or UMN signs in two body regions, or
UMN and LMN signs in two regions with no UMN signs
rostral to LMN signs.
It has to be taken into consideration that the El Escorial
criteria were developed for research and may be too
restrictive for clinical use. In one series, 44% of patients
did not meet criteria for at least probable ALS at diagnosis,
and 10% did not meet criteria even at death [13].
The most important diagnostic tool in the diagnosis of
ALS is the EMG examination. EMG is able to detect signs
of a LMN lesion in muscles that are apparently unaffected,
therefore increases the degree of evidence of the diagnosis,
mainly in patients with a predominantly UMN picture or a
clinically restricted syndrome. The required EMG findings
by the El Escorial criteria cited above are signs of
denervation (fibrillations) aside fasciculations and signs of
re-innervation. Another set of electrodiagnostic criteria,
termed “Awaji criteria”, was proposed recently in order to
facilitate earlier diagnostic characterization for clinical
purposes. This set of criteria broadens the electrophysiologic
characterization of ALS to include signs of chronic
denervation as equivalent to clinical signs of LMN involve-
ment. In addition, the same criteria propose that in the
context of suspected ALS fasciculation potentials should be
considered equivalent to signs of active denervation [14].
Neuroimaging studies and other laboratory tests are used
to exclude alternative diagnoses. At times, a brain MRI may
show bilateral hyperintensities on fluid-attenuated inversion
recovery sequence (FLAIR), corresponding to the degener-
ation of the corticospinal tracts, but the finding is neither
specific, nor frequent enough in order to be of use in the
diagnostic confirmatory process [15]. Developments of
more advanced neuroimaging techniques for confirmation
of subclinical UMN involvement are currently underway, as
functional MRI (fMRI) [16] and diffusion-tensor imaging
(DTI) [17].
The differential diagnosis includes other diseases of the
UMN, as multiple sclerosis, primary lateral sclerosis,
degenerative processes of the cervical spinal cord,
syringomyelia, and other diseases that lead to muscle
weakness and wasting, as inclusion body myositis [18],
post-polio-syndrome, multifocal motor neuropathy with
conduction block, paraneoplastic LMN syndromes [19].
Rare motor neuron diseases, as spinobulbar muscular
atrophy (Kennedy disease) [20], adult GM2 gangliosidosis
(hexosaminidase A deficiency) [21], juvenile muscular
atrophy of distal upper extremity (Hirayama disease) [22]
have to be ruled out in specific patients.
An incorrect diagnosis of ALS can have devastating
emotional and social consequences for patients and their
families, and it can delay appropriate treatment of an
alternative disease process; therefore, it is important to
consider diseases that can mimic ALS or that can contribute
to the patient’s symptoms.
Genetics
Familial ALS
Approximately 5–10% of ALS cases are familial (FALS)
with a Mendelian pattern of inheritance. The disease is
transmitted in an autosomal dominant fashion in most
cases. Mean age at onset is 10–20 years younger in patients
with FALS than in patients with sporadic disease, and
variability between families is greater than variability within
families. Most cases of FALS are indistinguishable from
sporadic disease; others have unique phenotypes [23, 24].
The first described and most frequent genetic abnor-
mality is a mutation in the copper/zinc superoxide
dismutase (SOD1) gene, on chromosome 21q, found in
10–20% of familial cases and 2% of patients with sporadic
ALS (SALS) [25]. More than 140 allelic variations have
been described in the SOD1 mutants, most of them are
single base substitutions leading to an amino acid
exchange. It is not yet known how mutant SOD1 causes
ALS, but mutations in the gene are thought to cause
disease through a toxic gain-of-function rather than
causing impairment of the antioxidant function of the
SOD1 enzyme [26]. The disease onset and duration are
reported to be closely linked to the type of SOD1
mutation. Certain SOD1 mutations are associated with
rapidly progressive disease and short survival, like A4V,
while others present with a relatively benign course [27].
The discovery that TDP-43 protein, encoded by TARDBP
gene on chromosome 1p (encoding the TAR-DNA binding
protein TDP-43), is a constituent of ubiquitinated inclusions
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in the cytoplasm of motor neurons of patients with SALS, as
well as in patients with non- SOD1 FALS and patients with
frontotemporal lobe dementia (FTLD) [28, 29] constituted an
important development in ALS research. TDP-43 is an RNA
processing protein that is normally found mainly in the cell
nucleus. Over 30 dominant mutations of the TARDBP gene
have been reported to date, accounting for 3% of patients
with both FALS and SALS [30–32]. A mutant mouse model
was recently described that develops a progressive and fatal
neurodegenerative disease with both ALS and FTLD
features [33].
Mutations in the fused in sarcoma/translated in lip-
osarcoma (FUS/TLS) gene were identified in 4% of FALS
[34, 35] and in very few SALS cases [36]. Interestingly,
like TDP-43, this gene has a putative role in RNA
regulation and is similarly translocated from the nucleus
to the cytoplasm in spinal cord motor neurons.
Mutations in alsin, vesicle associated membrane protein,
angiogenin, senataxin and a mutation in the p150 subunit of
dynactin have also been reported in rare cases, and linkages
to more loci without identification of a gene have been
described (reviewed in 24), but still a majority of patients
with FALS harbor a not yet detected genetic defect.
Known genes and linkages associated with familial ALS
are summarized in Table 1.
Sporadic ALS
The causes of SALS are still unknown. It is considered to
be a multifactorial disease, in which both environmental
and genetic factors interplay to trigger disease onset and
progression. The completion of a haplotype map of the
human genome [37] and development of advanced geno-
typing technology have enabled the performance of
genotype-wide association studies (GWAS). The genome-
wide SNP association analysis is a powerful, relatively new
method to identify, in an unbiased manner, genetic loci and
genes underlying complex diseases. SNP arrays allow
large-scale linkage analysis, association, and copy number
studies. A number of GWAS have been performed in
SALS, however to date these methods have not revealed
reproducible potential links to ALS [38–41]. This is due
probably to a large degree of genetic heterogeneity as well
as to the possibility that disease susceptibility is influenced
by additional environmental factors.
An exciting finding was reported by one of the most
recent and largest GWAS analyses of SALS to date:
although the analysis did not reveal any correlation with
risk of disease, it demonstrated for the first time an
association between a gene (kinesin-associated protein
3-KIFAP3) and survival. Patients who were homozygotes
for the favorable allele of the gene survived on average
14 months longer than heterozygotes and homozygotes for
the unfavorable allele. This is the first evidence that
genetic factors can modify disease phenotype [42].
A further remarkable finding, with still unclear signifi-
cance, is that of a specific variant in the chromogranin B
(CHGB) gene that is present in 10% of ALS patients, both
sporadic and familial, and in only 4.5% of controls,
conferring a 2.2-fold greater relative risk to develop ALS.
Table 1 Genes and linkages involved in familial ALS
Disease name Genetic locus Protein name Gene symbol Inheritance Incidence in familial ALS
ALS1 21q22.1 Cu–Zn superoxide dismutase 1 SOD1 Dominant 10–20%
ALS2 2q33 Alsin ALS2 Recessive Rare
ALS3 18q21 unknown unknown Dominant Rare
ALS4 9q34 Senataxin SETX Dominant Rare
ALS5 15q15.1–21.1 unknown unknown Recessive Rare
ALS6 16q12 Fused in sarcoma FUS Dominant
Recessive
4%–5%
ALS7 20p13 unknown unknown Dominant Rare
ALS8 20q13.3 Vesicle-associated membrane
protein-associated protein B
VAPB Dominant Rare
ALS9 14q11.2 Angiogenin ANG Dominant Rare
ALS10 1p36.2 TAR-DNA binding protein 43 (TDP-43) TARDBP Dominant 1–4%
ALS? 2p13 Dynactin 1 DCTN1 Dominant Rare
ALS-FTD1 9q21–22 unknown unknown Dominant unknown
ALS-FTD2 9p13.2–21.3 unknown unknown Dominant unknown
ALS-FTD with
Parkisonism
17q21.1 Microtubule-associated protein tau MAPT Dominant Rare
ALS-X Xcen unknown unknown Dominant Rare
ALS amyotrophic lateral sclerosis; FTD Frontotemporal dementia
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The same variant was associated with an earlier age at onset
by almost ten years in both SALS and FALS patients,
therefore the CHGB gene is apparently both a susceptibility
and a phenotype modifier gene [43]. The results of both last
studies await further confirmation from other populations.
Individual risk factors
It should be remembered that association is not cause, but
rather the first step in identifying a possible risk factor.
When applying an evidence-based approach to the analysis
of the epidemiological data, smoking exposure, including
patients who stopped smoking, was the only established
exogenous risk factor for occurrence of ALS [44, 45].
No other risk factor has attained this level of certainty
regarding its association with ALS. Head trauma, physical
activity, residence in rural areas, and alcohol consumption
were not proven as risk factors for ALS, although
implicated in certain studies [46]. Specific occupational
exposures are also mentioned as a risk factor for ALS,
although analyses of occupation as potential determinants
of ALS did not reach a definitive conclusion [47].
Two putative risk factors that have gained recent
attention include military service during the Gulf War
[48, 49], and being a soccer player [50, 51]. However, the
level of evidence supporting their role in triggering ALS is
low [52, 53].
The use of statins has been mentioned as possibly
associated with an increased incidence of ALS [54], but an
analysis by the US Food and Drug Administration (FDA),
undertaken after the agency received a higher than expected
number of reports of the occurrence of ALS among
individuals on statins, failed to reveal an increased
incidence of ALS in subjects treated with statins compared
with placebo [55].
Individual metabolic traits encountered frequently in
the general population were implicated recently as
possible modulatory factors, able to influence prognosis
in affected individuals. It was shown that an abnormally
elevated low-density lipoprotein (LDL) / high-density
lipoprotein (HDL) ratio increased mean patient survival
by more than 12 months [56]. Another study demonstrated
that ALS patients had lower mean serum uric acid levels
than healthy individuals. The decreased uric acid levels
were correlated to the rate of disease progression [57].
Pre-existent diabetes mellitus was shown to delay the
onset of ALS-related symptoms by 4 years in another
study [58]. Interestingly, all these metabolic factors are
considered detrimental in the daily clinical practice, but
for ALS patients they carried a favorable prognosis.
Probably they are also interrelated, but were not analyzed
as a group yet.
Pathophysiology and pathogenesis
Involvement of non-neuronal cells
Most insights into the pathogenic mechanisms of ALS in the
past decade came from studies in transgenic mice carrying
the human SOD1 mutation. SOD1 is a ubiquitously
expressed cytoplasmic enzyme that converts superoxide
anions to hydrogen peroxide. However, mutant SOD1
confers its toxic properties without altering enzymatic
activity [59–62].
Amajor contribution to understanding disease mechanisms
was the discovery that ALS is not just cell-autonomous, but is
influenced by the surrounding environment, namely by the
interaction between motor neurons and non-neuronal cells,
mainly glial cells. Initial experiments that selectively
expressed mutant SOD1 in motor neurons or glial cells did
not induce motor neuron degeneration or disease [63–65]. An
elegant experiment in chimeric ALS mice demonstrated that
wild-type non-neuronal cells extended survival of SOD1
mutant motor neurons in ALS mice, implicating that
neighboring non-neuronal cells are important in determining
survival [66]. The same study reported pathological abnor-
malities and cell death in wild-type motor neurons adjacent
to mutant SOD1-expressing non-neuronal cells. Thus, the
vulnerability of motor neurons to SOD1-mediated toxicity
appears to be influenced by their cellular environment,
created by their adjacent non-neuronal cells. Astrocytes that
express mutant SOD1 secrete probably factors that are toxic
to motor neurons, although such factors have not yet been
identified [67].
It has also been demonstrated that selective reduction in
mutant SOD1 expression within microglia [68, 69] and
astrocytes [70] significantly slows disease progression, but
does not affect the timing of disease onset. Evidence that
disease onset might have different genetic and cellular
mechanisms than disease progression comes from the
recent finding that selective down-regulation of mutant
SOD1 solely within the postnatal motor neurons signifi-
cantly slowed disease onset without affecting disease
progression [71].
Glutamate excitotoxicity
Glutamate-mediated excitotoxicity was the first proposed
mechanism of motor neuron degeneration in ALS, follow-
ing the finding of increased levels of glutamate in the
cerebrospinal fluid of ALS patients [72]. ALS has been
associated with reductions in the level of the glial cell
excitatory amino acid transporter EAAT2 [73]. This defect
might lead to an abnormal accumulation of extracellular
glutamate and subsequently repetitive firing of motor
neurons.
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Free radical damage
The concept that oxidative damage is involved in ALS was
based on the discovery that mutations in the SOD1 gene
cause FALS. Increased levels of 3-nitrotyrosine, a marker
for peroxynitrite–mediated oxidative damage, have been
reported in ALS patients [74]. Peroxynitrite causes cell
damage by nitration of tyrosine residues in target proteins.
We have just recently reported that ALS patients have a
significantly lower level of uric acid, a peroxynitrite
specific antioxidant, compared to control subjects and that
the concentration of uric acid was reversely correlated with
the rate of disease progression [57]. Nevertheless, although
oxidative damage has been linked to neurodegeneration,
many antioxidants tested in clinical trials have failed to
show benefit.
Intracellular aggregates
Ubiquinated inclusions containing pathologic forms of
TAR DNA-binding protein-43 (TDP-43) were identified
in the cytoplasm of motor neurons of patients with
SALS, non-SOD1 FALS and patients with frontotemporal
dementia [28, 29, 75, 76]. Cases with SOD1 mutations
had ubiquitin-positive neuronal inclusions; however, they
were not immunoreactive for TDP-43. These findings
implicate a common pathogenesis in SALS and non-SOD1
FALS. In contrast, the absence of pathological TDP-43 in
cases with SOD1 mutations implies that motor neuron
degeneration in these cases may result from a different
mechanism.
Alteration in RNA processing
Both TDP-43 and FUS/TLS are genes that encode RNA
processing proteins [35]. Patients with the FUS/TLS
mutations have cytoplasmic inclusions containing FUS/
TLS but not TDP-43. TDP-43 and FUS/TLS have striking
structural and functional similarities, implicating alter-
ations in RNA processing as a key event in ALS
pathogenesis and as a main target for future therapeutic
agents.
Mitochondrial dysfunction
Morphological and functional defects in mitochondria
were found in both human patients and ALS mice. Mutant
SOD1 was found to be associated with mitochondria and
subsequently impairs mitochondrial function. Recent
studies suggest that axonal transport of mitochondria
along microtubules and mitochondrial dynamics may be
disrupted in ALS (reviewed in [77]). Creatine, an agent
that improves mitochondrial function, has been shown to
be neuroprotective in animal models of ALS [78];
however, in humans creatine showed only a trend
toward beneficial effect in survival and did not influence
motor, respiratory or functional measures in ALS
patients [79].
Lack of neurotrophic factors, caspase-mediated cell
death (apoptosis) and inflammation are also possible
mechanisms involved in ALS (reviewed in [80, 81]).
In spite of major scientific achievements in the field
during the last years, the exact mechanisms responsible for
the onset and progression of motor neuron degeneration
remain largely unknown.
Treatment
The management of ALS nowadays is based on the
recognition of the importance of multidisciplinary care.
Although there is no cure for the disease, many of the
symptoms that develop during the course of the disease are
treatable and it is crucial to consider adjunctive measures to
maintain function and independence and improve quality of
life in patients with ALS. The improvement in symptomatic
care of the patients during the last decade led to an
improved rate of survival [82].
Non-drug therapy
Ventilatory management
Respiratory insufficiency is a common feature in patients
with ALS, usually in advanced stages, although it may be
the presenting clinical symptom in certain cases, and is the
most frequent cause of death.
The respiratory status in ALS patients should be
monitored serially by measurement of forced vital capacity
(FVC) or sniff nasal pressure and questioning the patient
about symptoms of respiratory insufficiency such as
insomnia, daytime fatigue, morning headaches. Overnight
pulse oximetry or polysomnography should be obtained as
clinically indicated.
Respiratory rehabilitation therapy such as insufflation-
exsufflation and chest physiotherapy can help maintain
lung function and avoid secondary atelectasis and
infections [83].
Non-invasive ventilatory support (NIV) should be
considered in patients with symptoms of respiratory
insufficiency when FVC (sitting or supine) is at or
below 50% of predicted normal; or if there is evidence
of nocturnal hypoventilation (O2 saturation <90%), even
if sitting and supine FVC are not significantly reduced.
NIV is usually provided by bi-level positive pressure
devices (BiPAP). The rationale of using NIV is that
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non-invasive ventilation can improve survival and
quality of life, and postpone the need for tracheostomy
[84, 85]. In patients with severe bulbar impairment, NIV
improves sleep-related symptoms, but it does not confer a
large survival advantage [84].
During the last years it has been recognized that
initiation of NIV might be indicated earlier than when
FVC drops below 50% predicted. Patients treated early
with NIV had an increased survival at one year and their
median decline in FVC was slower than in patients who
did not use NIV [86]. A Cochrane review analyzed
recently the efficacy of NIV for ALS and concluded that
NIV is able to prolong survival and to improve and
maintain quality of life [87]. Similarly, a revision of the
Practice Parameters of the American Academy of
Neurology published in 2009 concluded that NIV is
probably effective in prolonging survival and in slow-
ing the rate of FVC decline, and possibly effective in
improving quality of life. Therefore NIV should be
considered to treat respiratory insufficiency in ALS
[88].
A new and different approach that is currently under
evaluation is the early (before significant diaphragmatic
muscle weakness and atrophy occurred) implantation of
electrodes into the diaphragm with subsequent electrical
pacing. The consequence of this technique is both an
immediate improvement of the diaphragm contraction
and inspiratory volume, and a long-term delay in the
development of muscle atrophy of the diaphragm with
slowing of respiratory deterioration. The technique is
apparently safe and reportedly able to postpone
invasive mechanical ventilation for up to two years
[89].
Nutritional management
In spite of decreasing movement abilities, patients with
ALS have increased needs for energy in form of caloric
intake [90, 91]. On the other hand the caloric intake is
frequently low as a consequence of impaired swallowing.
Dysphagia is common in ALS and leads to increased risk
of aspiration, malnutrition, weight loss and dehydration.
Enteral tube feeding is commonly used in ALS to maintain
adequate nutrition and hydration. This is most commonly
performed by percutaneous endoscopic gastrostomy
(PEG) and in fewer cases by radiologically inserted
gastrostomy (RIG). Enteral nutrition should be initiated
early after symptom onset in order to minimize complica-
tions and weight loss. Enteral nutrition via PEG is
recommended by the revised Practice Parameters of the
American Academy of Neurology, as it stabilizes body
weight and improves survival in both bulbar and limb
onset patients [88].
Communication
Verbal communication is for most humans one of the most
important functions, as it determines the ability to initiate
and maintain social interactions, and dominates the
evaluation of percepted quality of life. Patients with
bulbar ALS lose their ability to speak relatively early in
the course of the disease. If the ability to write or use a
keyboard is preserved, patients switch to written commu-
nication. But with progressing disease the hands become
weak too, and more sophisticated communication aids are
needed. Computer interfaces are being developed that can
be activated by the patient through fixation with his eyes
at a keyboard on a screen (Fig. 2), or even by patient’s
thought and registration of the pattern of his brain EEG
activity [92].
Exercise and physical therapy
Performance of physical activity was considered in the past
as possibly harmful for patients with ALS, but during the
last decade there is rather robust evidence that regular
moderate exercise is able to decrease the rate of deterioration
in disability in ALS patients [93, 94].
Physical therapy is indicated to preserve range of motion of
joints and avoid secondary pain, contracture, muscle spasms.
Multidisciplinary care
Specialized ALS centers were established at many sites
throughout US and Europe; they have the experience and
resources to manage ALS patients and offer high level
standard of care. Multidisciplinary care may have a survival
benefit in ALS [95].
Fig. 2 This 40-years-old patient is completely paralyzed and
mechanically ventilated. He chooses letters on a computer screen
with light beams refracted by his eye balls. He wrote in this way (in
hebrew on the top of the screen): “I am completely paralyzed, there is
no single part of my body that I can move”
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Drug therapy
Contemporary therapies
Inferences from animal models, including transgenic
models of familial disease, to sporadic human disease are
not straightforward. However, recognition of the role of
glutamate excitotoxicity in sporadic disease and in animal
models led to the development of riluzole, the only
treatment that has been shown to ameliorate the course of
sporadic ALS [96, 97]. The mechanism of action of riluzole
includes interference with N-methyl-D-aspartate (NMDA)
receptor mediated responses, stabilization of voltage-gated
sodium channels, inhibition of glutamate release from
pre-synaptic terminals, and increasing extracellular glutamate
uptake [98].
Two randomized, controlled clinical trials have shown
that riluzole prolongs survival in patients with ALS
[96, 97]. The results of a recent meta-analysis indicate that
riluzole at a dose of 100 mg daily is safe and probably
prolongs survival by approximately 2–3 months in patients
with ALS [99].
Additional drug therapy exists to manage symptoms of
ALS. Adequate symptomatic treatment of ALS can alleviate
patient discomfort. Sialorrhea and emotional lability are
bothersome and often socially embarrassing to ALS patients.
Sialorrhea can be treated with amitriptyline, glycopyrrolate,
or transdermal scopolamine patches; if sialorrhea is refrac-
tory, radiation therapy of the salivary glands or botulinum
toxin injections of the salivary glands can be offered [100].
Thick mucus is amenable with propranolol or metoprolol.
Pseudobulbar affect or emotional lability is treated with
dextromethorphan/ quinidine, amitriptyline or fluvoxamine.
Anxiety, depression, pain, and muscle discomfort
impair quality of life of patients and often of their
caregivers. Depression can be treated with tricyclic
antidepressants such as amitriptyline or newer agents
such as sertraline. Anxiety can be treated with anxio-
lytics such as benzodiazepines. Pain should be treated
with anti-inflammatory and non-narcotic analgesic drugs
or combinations; opioid analgesics should be considered
if pain is refractory or in later disease stages. Muscle
stiffness and spasticity can be treated with muscle
relaxants such as baclofen or tizanidine. A recent study
showed a positive effect of the anticonvulsant drug
levetiracetam on muscle cramps and spasticity [101].
Fatigue may be a disabling symptom unrelated to muscle
weakness or quality of sleep; in these patients modafinil
may be indicated [102]. Insomnia causes nighttime distress
and interferes with daytime functioning and well-being.
Insomnia should be treated with non-invasive ventilation,
pain management, antidepressants, or hypnotics, depending
on the suspected cause.
Future therapies and directions
Despite the advances in understanding disease mechanisms
and the performance of many clinical trials, no new therapy
for ALS has been discovered during the last 15 years,
although few clinical trials gave a slight cause for cautious
optimism. Here are some of the more promising novel
treatment approaches for ALS:
Drugs intended to lower glutamate exitotoxicity
Talampanel (Teva)—it is a non-competitive antagonist of
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA). A double-blind, placebo-controlled, randomized
clinical trial of nine months duration was conducted in
59 patients with ALS, with 40 subjects receiving
talampanel and 19 subjects receiving placebo. Talampa-
nel was well tolerated and although no efficacy measure
reached statistical significance, there was a trend
towards slower decline of functional measurements and
muscle strength [103]. A large phase II trial with more
than 500 participants is ongoing. Results are expected
mid-2010.
Ceftriaxone (Hoffman LaRoche)—a further drug aimed
at glutamate toxicity, used clinically as a wide spectrum
antibiotic. In a novel attempt to widen the search for
potential therapeutic agents, an in vitro screening of 1040
FDA approved drugs in over 28 assays relevant to various
neurodegenerative disorders was performed. Several ceph-
alosporins showed hits in ALS relevant assays. Ceftriaxone
is a third generation cephalosporin with good penetration
into the central nervous system and a long half-life. It
increases expression of the glutamate transporter excitatory
amino acid transporter 2 (EAAT2) and glutamate uptake in
cultured astrocytes [104]. Ceftriaxone has been shown to
triple EAAT2 activity in mouse brains and increased
lifespan, strength, and neuron survival in ALS transgenic
mice [105]. A Phase I trial and compassionate use study
have been completed; a multicenter phase III study, aiming
for 600 subjects, started enrolling in May 2009 in order to
determine safety and effectiveness of long-term use of the
drug in patients with ALS.
The pharamaceutical company Avanir has announced
positive results for its phase 3 trial to treat emotional
outbursts, with uncontrollable episodes of laughing and
crying in patients with ALS and multiple sclerosis using
its experimental drug Zenvia. Zenvia is a combination of
two drugs, dextromethorphan, which supresses glutamate
release, and quinidine, which inhibits the breaking down
of dextromethorphan [106]. The drug significantly re-
duced the number of pseudobulbar episodes compared
to placebo. The drug was generally safe and well
tolerated.
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Protection of motor neurons
The experimental compound SB509 (Sangamo BioScien-
ces) appears safe and well-tolerated and may have a
positive effect on function in patients with ALS. The
compound contains a gene for an activator of vascular
endothelial growth factor A (VEGF-A). VEGF-A increases
production of blood vessels and may protect or nourish
nerve cells. Reduced VEGF-A expression in the spinal cord
leads to ALS-like symptoms [107], excess VEGF-A delays
neurodegeneration and extends survival in a transgenic
mouse model of ALS [108, 109]. In addition, a mutation in
the VEGF-A promoter is associated with risk for ALS in
males [110]. An open-label Phase II trial with intramuscular
injections in the neck, arms and legs or only in the legs in
45 ALS patients is ongoing. Estimated completion date is
June 2010.
Arimoclomol activates chaperones—misfolded proteins
(reviewed in [111]). According to CytRx, the developing
company, arimoclomol can detect proteins that are
misfolded and potentially toxic and refold them into their
correct, nontoxic shapes. A 3-months phase IIa trial in
patients with ALS demonstrated safety of the drug [112]
and another study, with participants with FALS caused by
mutations in the SOD1 gene, is currently being conducted.
A multicenter dose-ranging clinical trial of arimoclomol is
planned.
Modulate the mitochondria
The experimental drug KNS760704 (Knopp Neurosciences)
was reported to be safe and well tolerated, and there were
indications of possible benefit, in 92 patients with ALS
within a nine months trial. KNS760704 is a synthetic amino-
benzothiazole with demonstrated activity in maintaining
mitochondrial function. It may protect nerve cells under
stress. The drug is a molecular mirror image of pramipexole,
a prescription medication approved for the treatment of
Parkinson’s disease and restless legs syndrome [113]. There
was a dose-related trend toward a slowed rate of disease
progression, and toward a survival benefit in the large dose
group compared to the low dose group [114]. The safety
results and the trends toward improved functional outcomes
and survival provide preliminary evidence supporting the
ongoing evaluation of KNS760704 in phase 3 clinical trials.
Olexosime (Trophos) is a small cholesterol-like molecule
that was discovered in a screening program aimed at finding
small molecules that promote motor neuron survival in
culture [115]. Olexosime interacts with the mitochondrial
permeability transition pore, possibly preventing it from
opening; this might help prevent apoptosis. In SOD1
transgenic mice the compound delayed disease onset and
extended survival. Olexosime has completed Phase Ib
studies in ALS patients. These clinical trials demonstrated
that the drug is well tolerated and has a good safety profile.
Olexosime is currently tested in an ongoing pivotal
efficacy study in ALS. Results of this study are expected
in mid-2011.
Silence SOD1 gene
ISIS 333611 from Isis Pharmaceuticals is an antisense
oligomer directed at SOD1, aimed to down regulate the
gene’s expression, as it does in a rat disease model, and
slow disease in patients with SOD1 mutations. It is the first
approach that is really directed toward a known target for
the disease. A multicenter Phase 1 safety trial is enrolling
patients with SOD1-related FALS. Estimated completion
date is December 2011.
Stem cells
Stem cell transplantation represents a new therapeutic
approach with the opportunity of either cellular replace-
ment, or trophic support for the existing cell population, or
both. Potentially pluripotent and multipotent stem cells
could be stimulated to develop into specialized cells that
represent a renewable reservoir of cells for transplantation.
A different approach is trophic and growth factor support,
such as delivering brain-derived neurotrophic factor or
glial-derived neurotrophic factor.
There are a number of different sources for stem cells,
ranging from embryonic, fetal, placental and cord blood to
adult tissues. The adult tissue stem cells include bone
marrow-derived cell populations such as the marrow
mesenchymal stem cells and hematopoietic stem cells,
blood hematopoietic stem cells and neuronal stem cells.
Adult mesenchymal stem cells may be the best choice for
cell therapy assuming that they can be harvested from the
patient and grown in sufficient amounts. They offer the
advantages of not raising any ethical problems, not
inducing immune rejection, are less prone to promote
tumors and are easily available.
All cell types can be administered by allogeneic or
autologous delivery. Cells can be transplanted intracere-
brally or directly into the spinal cord, or infused by an
intravenous, intrathecal or intramuscular route. A further
approach is mobilization of endogenous progenitor stem
cells from the bone marrow into the peripheral blood by
cytokines such as granulocyte colony-stimulating factor.
The first FDA approved clinical trial to test stem cell
treatment for ALS is ongoing. This phase I trial intends to
study the effects of injecting human neural stem cells
(Neuralstem) into the spinal cords of patients with ALS.
These cells have already shown promise in transgenic
SOD1 rats, in which they differentiated into neurons that
EPMA Journal (2010) 1:329–341 337
formed synapses with host nerve cells, expressed and
released neurotrophic factors and delayed disease onset
and progression [116]. The study focuses on the safety of
the transplantation procedure.
Stem cells collected from blood [117] and bone marrow
[118] have also been tested in ALS. The autologous
transplantation of hematopoietic CD133(+) stem cells into
the frontal motor cortex was safe and well-tolerated in ALS
patients and delayed disease progression [117]. The
autologous transplantation of mesenchymal stem cells into
the spinal cord of ALS patients seems safe and might be
useful for future ALS clinical trials [118].
A different approach is being used by Brainstorm, an
Israel-based company that develops mesenchymal stem cell
lines that are able to secrete neurotrophic factors. A small
clinical trial in ALS patients is planned, with injection of
those cells into muscles in an attempt to deliver neuro-
trophic factors to the anterior horn cells by their uptake into
nerve terminals and retrograde axonal transport.
The recent development of induced pluripotent stem
cells (iPSC) by re-programming human skin fibroblasts is
promising. Dimos et al. [119] demonstrated the feasibility
of re-programming adult skin fibroblasts into embryonic
stem cells that can subsequently yield patient-specific
neural cells (neurons and astroglial cells). They not only
demonstrated that human disease-related neural cells can
be generated from adult fibroblasts via the generation of
iPSC, but also that the method can be successfully applied
to fibroblasts derived from elderly patients, a crucial issue
for age-dependent diseases. The generation of pluripotent
stem cells from an individual patient’s somatic tissues
would enable large scale production of the cell types
affected by the patient’s disease. These cells could in turn
be used for better understanding of disease mechanisms,
drug development and autologous cell replacement therapies.
Conclusions and prospects for the future
The last decade of basic and clinical research was very fruitful
for the ALS community, with plenty of exciting news that
improve our understanding on the different aspects of this
dreadful disease. We are at the edge of a new era, as we just
begin to understand the basic processes that lead to individual
differences in clinical presentation, course of disease and
ultimately survival between ALS patients, either due to
differences in genetic background, in the familial as well as
in the much more common sporadic form, or due to other
individual traits, as concomitant diseases and medications, life
style and exogenous exposures.
Understanding these individual differences between
patients will lead us to a more personalized approach in
the treatment. The first hints for this approach are
treatments being developed for patients carrying SOD1
mutations. As more genes are being discovered, treat-
ments directed toward silencing these other genes will
follow. Recommendations for changes in life style and
environmental exposures for specific groups of patients
and asymptomatic gene carriers are close to come. As
opposed to the present clumping together of patients with
various clinical forms and genetic and environmental
backgrounds and offering them a common form of
treatment, we can foresee for the next decade a splitting
of the syndrome into subtypes, for which different
diagnostic and treatment approaches will be used.
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